#5982
NEW REGISTRY CREATED FOR PAH PATIENTS
A new US-based study entitled, The Registry to Evaluate Early And Long-term PAH Disease Management (REVEAL), has been implemented at 50 sites in the US, for the purpose of gathering current and reliable information about the demographics, clinical course, and management of patients with pulmonary arterial hypertension (PAH). Patients will be followed for 5 years, and there are currently 1,226 patients enrolled in the registry. Researchers and representatives from Duke University, the Universities of Colorado, Alabama, and Oklahoma, and Actelion Pharmaceuticals suggest the registry will provide a large data set on PAH, which will allow the investigative community to address clinically important questions.
#6036
REVEAL REGISTRY RECOGNIZES DIAGNOSIS DELAY
As part of an observational, US-based study, the REVEAL Registry has identified a significant delay in the period spanning symptom onset and the time to diagnosis of pulmonary arterial hypertension (PAH). Researchers and representatives from LDS Hospital, Boston University, Baylor College, the University of Utah, and the Ovation Research Group examined the records of REVEAL enrollees who had physician diagnosed PAH. They found that most of the patients experienced a significant delay between first symptoms and time to diagnosis, with most experiencing a year-long delay. They also note that 25 percent experienced a delay of up to 3-years.
#5900
SILDENAFIL BEST TREATMENT FOR PAH
Sildenafil may be the best treatment for pulmonary arterial hypertension (PAH), according to new research. The study, from the Medical University of South Carolina, found that when compared to six other treatments, Sildenafil was the most inexpensive, and resulted in a greater gain in quality-adjusted life years. Researchers suggest physicians take the life-styles of their patients into account when prescribing PAH medications.